Cellectar Biosciences announces 'significant' PDC platform advancement
Cellectar Biosciences announces that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone. Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company's PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells. To date, the company's research has demonstrated that the conjugated molecules are inactive until cleavage of the payload from the phospholipid ether. This mechanism provides significant opportunity to reduce the off-target impact and associated side effects of many chemotherapeutics. These data show greater than 500-fold dilution separation between effects in tumor cells and effects in normal cells, and that this separation can be controlled by the linker chemistry. Importantly, the company has also been able to show that its novel linker chemistry allows for the payload to be selectively cleaved within the tumor cells, resulting in significant potency.